KDM1A and neuroblastoma: Although MAOIs are very effective in vitro, and they did significantly suppress the growth of neuroblastoma xenograft tumors in mice, their lack of specificity for KDM1A requires treatment with high doses, which cause extensive side effects in whole animal testing models [18].